2018
DOI: 10.1155/2018/4507638
|View full text |Cite
|
Sign up to set email alerts
|

Iatrogenic Spinal Subdural Hematoma due to Apixaban: A Case Report and Review of the Literature

Abstract: In the last decade, the clinical relevance for developing safer oral anticoagulants prompted the development of new classes of drugs that have shown a lower risk of life-threatening bleeding events as compared to standard warfarin. Nontraumatic spinal subdural hematoma is an uncommon urgent complication that can be associated with the use of these agents. An unusual case of spinal subdural hematoma related to apixaban treatment for nonrheumatic atrial fibrillation is reported here.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
13
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(14 citation statements)
references
References 16 publications
1
13
0
Order By: Relevance
“…ere was no associated bleeding with either surgical intervention. On the other hand, 5 cases (including this report) had delayed surgical intervention (>24 hours) [5][6][7][8][9]. Among these cases, only 2 had good recovery (40%), and 3 had bad outcomes.…”
Section: Discussionmentioning
confidence: 80%
See 1 more Smart Citation
“…ere was no associated bleeding with either surgical intervention. On the other hand, 5 cases (including this report) had delayed surgical intervention (>24 hours) [5][6][7][8][9]. Among these cases, only 2 had good recovery (40%), and 3 had bad outcomes.…”
Section: Discussionmentioning
confidence: 80%
“…Since the first description of a case of SH associated with the use of a DOAC (rivaroxaban) in 2012 [1], there have been a total of 10 other reports describing both SSEH and spinal subdural hematomas (SSDHs) in association with different DOACs [2][3][4][5][6][7][8][9]. As the use of DOACs continues to increase [10], more similar cases are expected to complicate treatment with these agents.…”
Section: Introductionmentioning
confidence: 99%
“…NOACs are increasingly used as alternatives to warfarin, as the latter has many potential limitations and side effects, including food drug interactions, delayed onset of action, narrow therapeutic window, and the need to close monitoring of the international normalized ratio plus a number of associated hemorrhagic adverse events. Apixaban is a direct factor Xa inhibitor and one of the new oral anticoagulants that has been shown to be effective in the reduction of stroke and embolic events in patients with nonvalvular atrial fibrillation [2]. A significant adverse effect of the drug is intracranial hemorrhage and traumatic spinal hematoma, although less common when compared with warfarin, especially in patients undergoing neuroanesthesia or spinal puncture [4].…”
Section: Discussionmentioning
confidence: 99%
“…Better outcomes can be expected with early neurological evaluation and intervention [8]. Conservative management might be considered in cases with mild neurological deficits, rapid spontaneous recovery, or high-risk surgical candidates [1,2,7].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation